[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640089":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":56,"collaborators":20,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":20,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Everest Medicines (China) Co.,Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EVER001 200mg bid","EXPERIMENTAL","Participants in this arm receive EVER001 200 mg administered twice daily (bid) orally. This single-arm cohort evaluates the efficacy and safety of EVER001 in subjects with FSGS, MCD, and IgA",[13],"Drug: EVER001",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","EVER001","EVER001 200 mg, oral administration, twice daily (bid), for the treatment of proteinuric glomerular diseases including FSGS , MCD , and IgA",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Fei Liao","CONTACT","+8621- 8012 5712","fei.liao@everestmedicines.com",[28,47],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Peking University First Hospital","RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Hong Zhang","+8610-83575530","hongzh@bjmu.edu.cn",{"facility":48,"status":30,"city":49,"state":50,"zip":20,"country":34,"countryCode":35,"cosmosGeoPoint":20,"geoPoint":20,"contacts":51},"Tianjin Medical University General Hospital","Tianjin","Hebei",[52],{"name":53,"role":24,"phone":54,"phoneExt":20,"email":55},"yan jun Jia","+86-13821735536","jiajunya@126.com",{"type":57,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100640089","phase-2-evaluate-the-efficacy-safety-pharmacokinetics-and-pharmacodynamics-of-ever001-in-participants-with-selected-proteinuric-glomerular-diseases-100640089",false,"NCT07614477","Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases","The Sub-Study 3 of A Phase 1b\u002F2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)","Inclusion Criteria:\n\n* Primary FSGS or MCD\u002FIgAN confirmed by renal biopsy\n* eGFR ≥ 45 mL\u002Fmin\u002F1.73 m²\n* For participants with FSGS or MCD: must have a 24-hour urine protein-to-creatinine ratio (UPCR) \\> 3.5 g\u002Fg and serum albumin \\\u003C 30 g\u002FL during the screening period\n* For participants in the IgAN group: 24-hour UPCR ≥ 0.8 g\u002Fg; ARB or ACEI stable for ≥ 12 weeks prior to Day 1\n* Patients with FSGS or MCD who have not been treated with immunosuppressants or are sensitive to prior immunosuppressant treatment\n\nExclusion Criteria:\n\n* Hereditary or secondary FSGS\u002FMCD; collapsing FSGS\n* BMI ≥ 35 kg\u002Fm² in participants with FSGS\u002FMCD\n* Evidence of diabetes mellitus or a history of diabetes mellitus\n* Acute or chronic infection requiring treatment\n* Patients infected with HIV, hepatitis C, syphilis, or hepatitis B\n* Patients with current or prior inadequately treated active tuberculosis (TB), latent TB, or evidence of current household contact with active TB\n* At risk of bleeding\n* Baseline 24-hour UPCR \\> 3 g\u002Fg and serum albumin \\\u003C 30 g\u002FL in participants with IgAN","ALL","18 Years","75 Years",{"count":69,"type":70},45,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This is a Phase 1b\u002F2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at \\~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.",[76,77,78],"Minimal Change Disease (MCD)","IgA Nephropathy (IgAN)","Focal Segmental Glomerulosclerosis (FSGS)","2026-05-22",{"date":81,"type":82},"2026-05-29","ACTUAL",{"date":84,"type":70},"2026-05-15",{"date":86,"type":70},"2029-03-31",{"name":5,"class":6},2]